Causes of Secondary and Tertiary Adrenal Insufficiency
Secondary adrenal insufficiency results from pituitary pathology causing ACTH deficiency, while tertiary adrenal insufficiency results from hypothalamic dysfunction or, most commonly, prolonged suppression of the hypothalamic-pituitary-adrenal (HPA) axis by exogenous glucocorticoid therapy.
Secondary Adrenal Insufficiency (Pituitary-Level Causes)
The most frequent endogenous cause of secondary AI is pituitary or hypothalamic tumors, which can cause ACTH deficiency either through direct mass effect or following treatment with surgery or radiation 1. These tumors typically present with panhypopituitarism rather than isolated ACTH deficiency.
Specific Pituitary/Hypothalamic Pathologies:
- Pituitary adenomas and other sellar masses - The most common structural cause 2
- Infiltrative lesions (sarcoidosis, histiocytosis, hemochromatosis)
- Infectious processes (tuberculosis, fungal infections)
- Vascular alterations (pituitary apoplexy, Sheehan syndrome)
- Traumatic brain injury
- Empty sella syndrome
- Genetic disorders (rare germline variants) 3
- Immune checkpoint inhibitor-related hypophysitis - An increasingly recognized cause 4
Key Clinical Distinction:
In secondary AI, both serum cortisol and ACTH levels are low, distinguishing it from primary AI where ACTH is compensatorily elevated 2. Patients lack the hyperpigmentation, hyperkalemia, and salt craving seen in primary AI because mineralocorticoid production remains intact 5.
Tertiary Adrenal Insufficiency (Hypothalamic-Level Causes)
Exogenous glucocorticoid therapy is by far the most common cause of tertiary AI and represents the most prevalent form of adrenal insufficiency overall 6, 7. The prevalence of iatrogenic AI far exceeds that of primary adrenal insufficiency 8.
Glucocorticoid-Induced Adrenal Insufficiency:
The mechanism involves prolonged suppression of hypothalamic CRH secretion by supraphysiologic glucocorticoid doses, leading to downstream ACTH and cortisol deficiency 7, 1.
Critical risk factors for glucocorticoid-induced AI include:
- Dose: Prednisone equivalent >5 mg daily carries significantly higher risk 6
- Duration: Prolonged therapy ≥3 months substantially increases risk 6
- Potency: More potent glucocorticoids (e.g., dexamethasone) carry higher risk
- Route: All routes can suppress the HPA axis, including oral, inhaled, topical, and intra-articular 6
- Frequency: Daily administration poses greater risk than alternate-day regimens
Other Tertiary Causes:
- Opioid-induced adrenal insufficiency - An emerging cause due to increased opioid use in pain management 4
- Hypothalamic tumors or infiltrative disease
- Sudden cessation or dose reduction of chronic glucocorticoids - Can precipitate adrenal crisis 6
Critical Clinical Pitfalls
Diagnostic Challenges:
The diagnosis is frequently delayed because symptoms are non-specific (fatigue, anorexia, nausea, weight loss, hypotension) and can be mistaken for the underlying disease being treated 5, 7. A Danish study found that after discontinuing prolonged glucocorticoids, patients had increased rates of hypotension (2.5-fold), GI symptoms (1.7-fold), and hyponatremia (1.5-fold) 6.
Adrenal Crisis Risk:
While less common than in primary AI, adrenal crisis can occur in secondary/tertiary AI, particularly during acute illness, surgery, or glucocorticoid dose reduction 4. One Dutch study found an incidence rate of 15.1 per 100 person-years in glucocorticoid-induced AI, higher than both primary and secondary AI from other causes 6. However, this must be interpreted cautiously due to small sample size and selection bias.
Mortality Considerations:
A UK study of 70,638 oral glucocorticoid users found a sharp increase in mortality during the first 2 months after glucocorticoid cessation, raising suspicion of undiagnosed adrenal crises 6. Supraphysiologic glucocorticoid doses (>5 mg prednisone equivalent daily) are associated with increased all-cause mortality (adjusted HR 1.97), with risk increasing with higher doses 6.
Recognition Strategy
In any patient with unexplained fatigue, hypotension, hyponatremia, or hypoglycemia, consider AI in the differential, particularly if they have:
- History of pituitary/hypothalamic disease or surgery
- Current or recent glucocorticoid therapy (any route, ≥3 months duration)
- Chronic opioid use
- Recent immune checkpoint inhibitor therapy
- History of traumatic brain injury or pituitary radiation
The key is maintaining high clinical suspicion, as no single test has sufficient sensitivity to identify all patients with secondary AI 1. Patients with suggestive symptoms and risk factors require careful assessment and follow-up 1.